Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

KRAS G12C inhibitor RO3903 overcomes resistance in preclinical models

RO3903 rapidly engages KRAS G12C, resists RTK-driven reactivation, and suppresses tumor growth in preclinical and intracranial models.

New U.S. data show colorectal cancer incidence is rising again across nearly every age group under 70, including…

A melanoma study ties ribosome biogenesis gene activity to immune state, prognosis, and FKBP4 as a candidate target…

NeuroMemory-DiffNet paired reference-guided memory with MRI to classify and segment brain tumors, reaching strong benchmark performance on two…

The American Cancer Society now recommends PSA testing every two years for average-risk men ages 50 to 69,…

A review links obesity most strongly to endometrial cancer, with weaker ovarian and cervical associations and new emphasis…

Randomized trials in resected colorectal cancer show ctDNA can guide chemotherapy de-escalation, but escalation and post-adjuvant treatment remain…

NRG Oncology outlines research gaps and trial design priorities for recurrent or metastatic head and neck squamous cell…

NIH research links higher PFOA and PFOS blood levels to greater ER-negative breast cancer risk, with no overall…

In 21,738 Japanese patients with type 2 diabetes, baseline glucose-lowering therapy was not linked to lower immune checkpoint…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds